Showing 39,781 - 39,800 results of 106,272 for search '(( 2 de decrease ) OR ( 5 ((point decrease) OR (((mean decrease) OR (a decrease)))) ))', query time: 1.67s Refine Results
  1. 39781

    A398 induces apoptosis in HL-60 cell line. by Alethéia L. Silveira (629767)

    Published 2014
    “…<p>Cells were treated with A398 (4, 6 and 8 µM) or etoposide (5 µM) for 1 h, 3 h or 6 h and stained with annexin V-alexa fluor 488 and PI or with TMRM. …”
  2. 39782
  3. 39783

    Effects of four different antihypertensive drugs on plasma metabolomic profiles in patients with essential hypertension by Timo P. Hiltunen (4582405)

    Published 2017
    “…Decreases of both systolic (P = 0.06) and diastolic (P = 0.04) blood pressure after amlodipine administration tended to associate with a decrease of plasma hexadecanedioate, a dicarboxylic fatty acid recently linked to blood pressure regulation.…”
  4. 39784

    Table2_Identification of an Autophagy-Related Gene Signature for the Prediction of Prognosis in Early-Stage Colorectal Cancer.XLSX by Xu-tao Lin (11756216)

    Published 2021
    “…The ATG signature, stratifying patients into high and low autophagy risk groups, was validated in the validation (HR, 2.29[1.15–4.55]; p = 1.5 × 10–2) and meta-validation cohorts (HR, 2.5[1.03–6.06]; p = 3.63 × 10–2) and proved to be prognostic in a multivariate analysis. …”
  5. 39785

    Image2_Identification of an Autophagy-Related Gene Signature for the Prediction of Prognosis in Early-Stage Colorectal Cancer.TIF by Xu-tao Lin (11756216)

    Published 2021
    “…The ATG signature, stratifying patients into high and low autophagy risk groups, was validated in the validation (HR, 2.29[1.15–4.55]; p = 1.5 × 10–2) and meta-validation cohorts (HR, 2.5[1.03–6.06]; p = 3.63 × 10–2) and proved to be prognostic in a multivariate analysis. …”
  6. 39786

    Data_Sheet_1_A Secondary Metabolism Pathway Involved in the Production of a Putative Toxin Is Expressed at Early Stage of Monilinia laxa Infection.xlsx by Maria Villarino (5543435)

    Published 2022
    “…We identified a class of genes highly expressed at 6 hpi and that their expression decreased to almost undetectable levels at 14 to 48 hpi. …”
  7. 39787

    Table_1_A novel form of transcutaneous electrical nerve stimulation for the reduction of dysesthesias caused by spinal nerve dysfunction: A case series.docx by Yuki Nishi (7486787)

    Published 2022
    “…Background<p>Current therapeutic interventions for dysesthesias caused by spinal cord dysfunctions are ineffective. We propose a novel intervention using transcutaneous electrical nerve stimulation (TENS) for dysesthesias, and we present an in-depth case series.…”
  8. 39788

    A Pilot Trial of a Sexual Health Counseling Intervention for HIV-Positive Gay and Bisexual Men Who Report Anal Sex without Condoms by Trevor A. Hart (256472)

    Published 2016
    “…</p><p>Trial Registration</p><p>ClinicalTrials.gov <a href="http://www.clinicaltrials.gov/ct2/show/NCT02546271" target="_blank">NCT02546271</a></p></div>…”
  9. 39789

    Table_2_A novel form of transcutaneous electrical nerve stimulation for the reduction of dysesthesias caused by spinal nerve dysfunction: A case series.docx by Yuki Nishi (7486787)

    Published 2022
    “…Background<p>Current therapeutic interventions for dysesthesias caused by spinal cord dysfunctions are ineffective. We propose a novel intervention using transcutaneous electrical nerve stimulation (TENS) for dysesthesias, and we present an in-depth case series.…”
  10. 39790

    Table_3_A novel form of transcutaneous electrical nerve stimulation for the reduction of dysesthesias caused by spinal nerve dysfunction: A case series.docx by Yuki Nishi (7486787)

    Published 2022
    “…Background<p>Current therapeutic interventions for dysesthesias caused by spinal cord dysfunctions are ineffective. We propose a novel intervention using transcutaneous electrical nerve stimulation (TENS) for dysesthesias, and we present an in-depth case series.…”
  11. 39791

    Image_1_Lipocalin 2 – mutation screen and serum levels in patients with anorexia nervosa or obesity and in lean individuals.pdf by Yiran Zheng (2562298)

    Published 2023
    “…The secondary structure change of lipocalin-2 due to LCN2-p.Val89Ile may decrease solubility and results in a low lipocalin-2 level in a heterozygotes carrier (female recovered from AN). …”
  12. 39792

    Flow chart of study selection. by Xu Han (141301)

    Published 2024
    “…ID=CRD42022339649" target="_blank">CRD42022339649</a>.</p></div>…”
  13. 39793

    DataSheet_1_Association between GLO1 variants and gestational diabetes mellitus susceptibility in a Chinese population: a preliminary study.zip by Qiaoli Zeng (9452591)

    Published 2023
    “…Conversely, the GLO1 rs4746 TG was associated with a decreased risk of GDM (TG vs. TT: OR = 0.740; 95% CI: 0.548-0.999; P = 0.049; TG vs. …”
  14. 39794

    A Functional Polymorphism (rs10817938) in the XPA Promoter Region Is Associated with Poor Prognosis of Oral Squamous Cell Carcinoma in a Chinese Han Population by Chunhai Gao (3117477)

    Published 2016
    “…In conclusion, the present study showed that XPA rs10817938 polymorphism is a functional SNP in <i>vitro</i> and in <i>vivo</i> and a biomarker for poor prognosis in OSCC patients.…”
  15. 39795
  16. 39796
  17. 39797
  18. 39798

    Flow chart of data screening and analysis. by Yan She (8639796)

    Published 2025
    “…In contrast, the BMD, BV/TV, and Tb.N in the 12-week model group exhibited a modest but non-significant decrease relative to the 9-week model group. …”
  19. 39799

    A watermaze protocol to examine competition of two memory traces. by Lisa Genzel (817546)

    Published 2017
    “…<p>(A) Rats learned two opposite hidden platform locations in a watermaze over two successive sessions (four blocks of two trials per block, separated by 7.5 h) with a probe trial (no platform) conducted 7 d later. …”
  20. 39800

    Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial by David R. Clemmons (765381)

    Published 2017
    “…Total cholesterol (-0.3±0.6 mmol/L) and non-HDL cholesterol (-0.3±0.5 mmol/L) significantly decreased from baseline to Week 12 in the tesamorelin 2 mg group (p<0.05 vs. placebo). …”